Food and Drug Administration has approved the ‌expanded use of Travere Therapeutics' ‌drug to treat a rare kidney disorder, ...

Travere Therapeutics, Inc. ( TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS April 13, 2026 6:45 PM EDT ...

The agency approved the drug in adult and pediatric patients aged 8 years and older. ・Travere expects that there are at least 30,000 people in the U.S. with focal segmental glomerulosclerosis but ...

ROCKVILLE, Md., April 13, 2026 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) announced today its 2026 Class of Corporate Members who serve as strategic partners in AKF's Corporate Membership ...

Travere Therapeutics received approval from the Food and Drug Administration for a treatment for a rare kidney disorder. The biopharmaceutical company said Monday the approval is for its Filspari drug ...

Bloom Energy , a global leader in power solutions, today announced an expanded partnership with Oracle to support the rapid buildout of its AI and cloud computing infrastructure. Under a master ...

FILSPARI indicated to reduce proteinuria in adults and children aged 8 years and older with FSGS who do not have nephrotic syndrome. Additional indication for FILSPARI expands tot ...

Avetta®, the leader in intelligent work readiness across global supply chains, has partnered with Australian mining and exploration company Aurelia Metals to improve its compliance rates through ...

Monday’s FDA approval makes Filspari the first therapy specifically indicated for FSGS, a condition that represents a $1 ...

The U.S. Food and Drug Administration has approved the expanded use of ​Travere Therapeutics' drug to treat a rare kidney ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

The FDA had extended the review of its supplemental New Drug Application for Filspari in January 2026. ・Citi kept a $48 price target for Travere, adding that it expects the FDA to approve the drug.